Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial

Abstract In this study, we investigated the effect of exenatide (EXE), a glucagon-like peptide (GLP)-1 receptor agonist, on kidney function, obesity indices, and glucose control in overweight/obese patients with type 2 diabetes mellitus (T2DM). A total of 159 overweight/obese patients with T2DM were...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chao Kang, Qiao Qiao, Qiang Tong, Qian Bai, Chen Huang, Rong Fan, Hui Wang, Kanakaraju Kaliannan, Jian Wang, Jing Xu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ff41a413345a4912b70a2f2d7da7fac4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ff41a413345a4912b70a2f2d7da7fac4
record_format	dspace
spelling	oai:doaj.org-article:ff41a413345a4912b70a2f2d7da7fac42021-12-02T19:16:14ZEffects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial10.1038/s41598-021-99527-y2045-2322https://doaj.org/article/ff41a413345a4912b70a2f2d7da7fac42021-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-99527-yhttps://doaj.org/toc/2045-2322Abstract In this study, we investigated the effect of exenatide (EXE), a glucagon-like peptide (GLP)-1 receptor agonist, on kidney function, obesity indices, and glucose control in overweight/obese patients with type 2 diabetes mellitus (T2DM). A total of 159 overweight/obese patients with T2DM were randomized to the EXE group or insulin glargine (GLAR) control group for a total treatment period of 24 weeks. EXE intervention significantly reduced the urine albumin concentration (UAC) at week 12 and 24 endpoints (P < 0.001 at week 12 and 24). The levels of the anthropometric, glucose and lipid parameters (TG and HDL-c), and inflammation biomarkers (CRP and TNF-α) in the EXE group were improved at 12 weeks or 24 weeks, respectively. Meanwhile, a comparison between two groups showed significant changes in anthropometric parameters, glucose parameters, lipid parameters (TG and HDL-c), and Inflammation biomarkers (CRP, IL-6, and TNF-α). Serum fibroblast growth factor 21 (FGF21) was increased in the EXE group (P = 0.005) at week 24, and the change was significantly improved compared with GLAR group (P = 0.003). Correlation network analysis showed that FGF21 had a more central role in improving metabolism in the EXE group, and the change of FGF 21 was significantly negatively correlated with UAC at week 12 and week 24, respectively (r = − 0.297, P = 0.010; r = − 0.294, P = 0.012). Our results showed that EXE could help patients improve UAC, glycemic levels, and inflammatory biomarkers after a follow-up period of 24 weeks intervention. These EXE effects may be partly mediated by FGF 21, indicating that EXE is an effective and safe way to control albuminuria in overweight/obese patients with T2DM.Chao KangQiao QiaoQiang TongQian BaiChen HuangRong FanHui WangKanakaraju KaliannanJian WangJing XuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chao Kang Qiao Qiao Qiang Tong Qian Bai Chen Huang Rong Fan Hui Wang Kanakaraju Kaliannan Jian Wang Jing Xu Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial
description	Abstract In this study, we investigated the effect of exenatide (EXE), a glucagon-like peptide (GLP)-1 receptor agonist, on kidney function, obesity indices, and glucose control in overweight/obese patients with type 2 diabetes mellitus (T2DM). A total of 159 overweight/obese patients with T2DM were randomized to the EXE group or insulin glargine (GLAR) control group for a total treatment period of 24 weeks. EXE intervention significantly reduced the urine albumin concentration (UAC) at week 12 and 24 endpoints (P < 0.001 at week 12 and 24). The levels of the anthropometric, glucose and lipid parameters (TG and HDL-c), and inflammation biomarkers (CRP and TNF-α) in the EXE group were improved at 12 weeks or 24 weeks, respectively. Meanwhile, a comparison between two groups showed significant changes in anthropometric parameters, glucose parameters, lipid parameters (TG and HDL-c), and Inflammation biomarkers (CRP, IL-6, and TNF-α). Serum fibroblast growth factor 21 (FGF21) was increased in the EXE group (P = 0.005) at week 24, and the change was significantly improved compared with GLAR group (P = 0.003). Correlation network analysis showed that FGF21 had a more central role in improving metabolism in the EXE group, and the change of FGF 21 was significantly negatively correlated with UAC at week 12 and week 24, respectively (r = − 0.297, P = 0.010; r = − 0.294, P = 0.012). Our results showed that EXE could help patients improve UAC, glycemic levels, and inflammatory biomarkers after a follow-up period of 24 weeks intervention. These EXE effects may be partly mediated by FGF 21, indicating that EXE is an effective and safe way to control albuminuria in overweight/obese patients with T2DM.
format	article
author	Chao Kang Qiao Qiao Qiang Tong Qian Bai Chen Huang Rong Fan Hui Wang Kanakaraju Kaliannan Jian Wang Jing Xu
author_facet	Chao Kang Qiao Qiao Qiang Tong Qian Bai Chen Huang Rong Fan Hui Wang Kanakaraju Kaliannan Jian Wang Jing Xu
author_sort	Chao Kang
title	Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial
title_short	Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial
title_full	Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial
title_fullStr	Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial
title_full_unstemmed	Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial
title_sort	effects of exenatide on urinary albumin in overweight/obese patients with t2dm: a randomized clinical trial
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ff41a413345a4912b70a2f2d7da7fac4
work_keys_str_mv	AT chaokang effectsofexenatideonurinaryalbumininoverweightobesepatientswitht2dmarandomizedclinicaltrial AT qiaoqiao effectsofexenatideonurinaryalbumininoverweightobesepatientswitht2dmarandomizedclinicaltrial AT qiangtong effectsofexenatideonurinaryalbumininoverweightobesepatientswitht2dmarandomizedclinicaltrial AT qianbai effectsofexenatideonurinaryalbumininoverweightobesepatientswitht2dmarandomizedclinicaltrial AT chenhuang effectsofexenatideonurinaryalbumininoverweightobesepatientswitht2dmarandomizedclinicaltrial AT rongfan effectsofexenatideonurinaryalbumininoverweightobesepatientswitht2dmarandomizedclinicaltrial AT huiwang effectsofexenatideonurinaryalbumininoverweightobesepatientswitht2dmarandomizedclinicaltrial AT kanakarajukaliannan effectsofexenatideonurinaryalbumininoverweightobesepatientswitht2dmarandomizedclinicaltrial AT jianwang effectsofexenatideonurinaryalbumininoverweightobesepatientswitht2dmarandomizedclinicaltrial AT jingxu effectsofexenatideonurinaryalbumininoverweightobesepatientswitht2dmarandomizedclinicaltrial
_version_	1718377009864769536

Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial

Ejemplares similares